Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2005 028 671.3 |
96 | EP file number | EAKZ | 05 79 7685.4 |
86 | WO file number | WAKZ | PCT/GB2005/004119 |
97 | EP publication number | EPN | 1812004 |
87 | WO publication number | WPN | 2006046024 |
54 | Designation/title | TI | ORTHO-KONDENSIERTE PYRIDIN- UND PYRIDIMIDIN-DERIVATE (Z.B. PURINE) ALS PROTEINKINASE-HEMMER |
51 | IPC main class | ICM (ICMV) | A61K 31/52 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 31/519 (2006.01), C07D 473/34 (2006.01), A61K 31/437 (2006.01), C07D 471/04 (2006.01), C07D 487/04 (2006.01) |
22 | DE application date | DAT | Oct 25, 2005 |
96 | EP application date | EAT | Oct 25, 2005 |
86 | WO application date | WAT | Oct 25, 2005 |
43 | Date of first publication | OT | May 4, 2006 |
| Date of publication of grant | PET | Jun 22, 2011 |
71/73 | Applicant/owner | INH | Astex Therapeutics Ltd., Milton Road, Cambridge, GB; Cancer Research Technology Ltd., London, GB; Institute of Cancer Research Royal Cancer Hospital, London, GB |
72 | Inventor | IN | SAXTY, Gordon, Cambridge CB4 0QA, GB; DA FONSECA, Tatiana Faria, Sutton SM2 5NG, GB; WOODHEAD, Steven John, Cambridge CB4 0QA, GB; BOYLE, Robert George, Cambridge CB4 0QA, GB; WYATT, Paul Graham, Cambridge CB4 0QA, GB; BERDINI, Valerio, Cambridge CB4 0QA, GB; COLLINS, Ian, Sutton SM2 5NG, GB; DONALD, Alastair, Oxfordshire OX14 4RY, GB; CALDWELL, John, Sutton SM2 5NG, GB; WALKER, David Winter, Cambridge CB4 0QA, GB |
74 | Representative | VTR | Stolmár & Partner Patentanwälte PartG mbB, 80331 München, DE |
| Address for service | | Stolmár & Partner Patentanwälte PartG mbB, 80331 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 621821 P Oct 25, 2004
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 684119 P May 24, 2005
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| GB 0423655 Oct 25, 2004
|
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
87 | WO language of publication | WLANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000001812004 Searchable text:
EP000001812004 Original document:
EP000001812004B1 Searchable text:
EP000001812004B1 Original document:
WO002006046024 Searchable text:
WO002006046024 |
43 | Date of first publication | EVT | May 4, 2006 |
| Date of the first transfer into DPMAregister | EREGT | May 26, 2011 |
| Date of the (most recent) update in DPMAregister | REGT | Sep 13, 2024 (Show all update days)(Hide all update days)- Sep 13, 2024
- May 26, 2011
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 7)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Jun 27, 2011 |
71/73 | Applicant/owner | INH | Astex Therapeutics Ltd., Milton Road, Cambridge, GB; Cancer Research Technology Ltd., London, GB; Institute of Cancer Research Royal Cancer Hospital, London, GB |
71/73 | Previous applicant/owner | INHF | Astex Therapeutics Ltd., Milton Road, Cambridge, GB, Cancer Research Technology Ltd., London, GB, Institute of Cancer Research Royal Cancer Hospital, London, GB |